Last close As at 05/08/2026
SEK1.39
▲ −0.01 (−0.43%)
Market capitalisation
SEK197m
Research: Healthcare
IRLAB Therapeutics has announced the appointment of Richard Godfrey as its new CEO, replacing Nicholas Waters. The new management structure will see Richard Godfrey focus on IRLAB’s commercial development, while Nicholas Waters (an IRLAB founder) will become vice president and head of R&D. He will lead further evolution of the company’s clinical assets and R&D platform. In our view, the move strengthens IRLAB’s management team and will allow the company to better focus on developing its main central nervous system assets, mesdopetam and pirepemat, along with its burgeoning preclinical pipeline and the Integrative Screening Process (ISP). Our estimates are under review.
Written by
IRLAB Therapeutics |
Richard Godfrey appointed as new CEO |
Management update |
Pharma and biotech |
14 June 2022 |
Share price performance
Business description
Analysts
IRLAB Therapeutics is a research client of Edison Investment Research Limited |
||||||||||||||||||||||||||||||||||||
IRLAB Therapeutics has announced the appointment of Richard Godfrey as its new CEO, replacing Nicholas Waters. The new management structure will see Richard Godfrey focus on IRLAB’s commercial development, while Nicholas Waters (an IRLAB founder) will become vice president and head of R&D. He will lead further evolution of the company’s clinical assets and R&D platform. In our view, the move strengthens IRLAB’s management team and will allow the company to better focus on developing its main central nervous system assets, mesdopetam and pirepemat, along with its burgeoning preclinical pipeline and the Integrative Screening Process (ISP). Our estimates are under review.
Year end |
Revenue |
PBT* |
EPS* |
DPS |
P/E |
Yield |
12/20 |
0.4 |
(91.7) |
(1.92) |
0.0 |
N/A |
N/A |
12/21 |
207.8 |
52.0 |
1.00 |
0.0 |
N/A |
N/A |
Note: *Reported.
Richard Godfrey joins IRLAB with more than 25 years of experience in the life science industry. He was previously chief operating officer at LifeArc after 12 years as CEO of the listed biotech company BerGenBio. As existing assets move through the development pipeline and the underlying ISP platform continues to deliver potential therapies, we see this newly focused management structure as a positive development for IRLAB.
IRLAB successfully out-licensed its lead asset, mesdopetam, to Ipsen in FY21 and has shifted its operational focus on developing its second asset, pirepemat, in falls and dementia in Parkinson’s disease. The company also has a burgeoning preclinical pipeline (IRL942, IRL757 and P003). All IRLAB’s assets have been discovered using the company’s proprietary R&D platform, the ISP.
|
||||||||||||
|
||||||||||||
Research: Healthcare
Midatech will be presenting interim data from its ongoing Phase I trial assessing lead asset MTX110 in diffuse intrinsic pontine glioma (DIPG) at the upcoming International Symposium on Pediatric Neuro-Oncology (ISPNO). The study is being conducted at the Columbia University Medical Center (CUMC) and the presentation will discuss preliminary results (safety signals) for seven of the 10 study participants. A highlight of this study is the use of an implantable continuous flow device to deliver MTX110 directly to the tumour (bypassing the blood-brain barrier), avoiding the need for new surgical insertions at each treatment cycle. The same device will be used in the company’s upcoming (H222) Phase I study in recurrent glioblastoma (rGBM). As a reminder, MTX110 holds orphan drug and fast track designations in the US for DIPG and GBM, respectively.